Yale Cancer Center

Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.

[Yale Cancer Center @YaleCancer]

On #BetweentheLines with @CancerNetwrk, Dr. Sarah Goldberg @YaleThoracic discusses #amivantamab every 4 weeks plus lazertinib as a first-line treatment for EGFR-mutated advanced #NSCLC.
https://t.co/5yVL63gOHu
@SmilowCancer

[Yale Cancer Center @YaleCancer]

A study from Drs. @mleapman + Xiaomei Ma @YaleSPH highlights how PSMA-PET imaging may shift #prostatecancer treatment patterns by detecting previously hidden metastases.
https://t.co/PIBxEmbUfP
@SmilowCancer @YaleCOPPER

[Yale Cancer Center @YaleCancer]

Study results from @Dr_AmerZeidan + colleagues in @NEJM demonstrate an all-oral regimen of decitabine–cedazuridine plus venetoclax is a viable treatment option for patients with #AML. 47% of pts achieved complete response & 63% had a complete or partial response.
https://t.co/qRE6ovpJJx
@SmilowCancer @YaleHematology @OncoAlert

[Yale Cancer Center @YaleCancer]

Findings from a study by Dr. Barbara Burtness highlight #amivantamab as a promising treatment option for patients with recurrent or metastatic #HNSCC who have exhausted standard therapies.
https://t.co/QfFgk50cnb
@SmilowCancer @JCO_ASCO #ASCO26

[Yale Cancer Center @YaleCancer]

.@MaxStahlMD will present "Expanding the Arsenal Against #Leukemia and #MyelodysplasticSyndromes' this afternoon at 12:21pm CDT. The oral abstract session will be co-chaired by @Dr_AmerZeidan.
https://t.co/udii6i5EZD
@SmilowCancer @YaleHematology @ASCO

[Yale Cancer Center @YaleCancer]

.@vedangiri will present 'Clinical Implications of Germline Variants in #ProstateCancer' and also serve as a panelist in an oral abstract session this morning at 11:21am CDT. #ASCO26
https://t.co/HpxnXyi9Sh
@SmilowCancer @ASCO

[Yale Cancer Center @YaleCancer]

Stem cell transplantation is the most cost-effective option for long-term care of #sicklecelldisease in adults compared to gene therapy and standard of care treatment, according to new research from @GeorgeGoshuaMD published in @BloodPortfolio.
➡️https://t.co/tLO7QddyxV
@SmilowCancer @ASH_hematology

[Yale Cancer Center @YaleCancer]

At 9:45am CDT #ASCO26, @Dr_AmerZeidan will co-chair and moderate the Q&A for an oral abstract session on #Leukemia, #MyelodysplasticSyndromes, and #Allotransplant. https://t.co/2i9QRmT03G
@SmilowCancer @YaleHematology @ASCO

[Yale Cancer Center @YaleCancer]

Great talk by @sundar__raghav at #ASCO26 on “Breaking the Immune Sanctuary: Targeting Metastatic Niches.” Metastasis may not be random—immune and cellular niches matter. These metastatic “sanctuary” sites can limit immunotherapy responses, underscoring the need for better treatment strategies. Understanding these niches may be the next frontier in cancer therapy. @ASCO @SmilowCancer @OncoAlert
@YaleGICancers

[Yale Cancer Center @YaleCancer]

.@AdrianaKahnMD shares data on a ph Ib trial #ASCO26: SIMONE (NCT06963905) tests whether adding immunotherapy to sacituzumab govitecan (SG) can improve outcomes in met #TNBC. Patients receive SG + nivolumab vs SG + nivolumab/relatlimab. #ASCO26 @ASCO @YaleBreast @SmilowCancer @OncoAlert

[Yale Cancer Center @YaleCancer]

At #ASCO26, @AdrianaKahnMD reported that primary #breastcancer tumors and skin metastases share many of the same DNA changes, though skin metastases more often had alterations linked to estrogen signaling and tumor spread. Targetable mutations were common in both, highlighting the value of genomic testing. @YaleBreast @ASCO @SmilowCancer @OncoAlert

[Yale Cancer Center @YaleCancer]

At #ASCO26, Dr. Tamar Kaminski shared that ~1 in 10 women ≥65 with advanced #breastcancer had an HRD genomic signature, potentially identifying patients for PARP inhibitor therapy. HRD+ tumors were enriched for BRCA1/2 and other DNA-repair alterations, supporting future PARP + immunotherapy studies. @YaleBreast @maryam_lustberg @ASCO @SmilowCancer @OncoAlert

[Yale Cancer Center @YaleCancer]

.@MaryamMooghali shares at #ASCO26: commercial pricing for biomarker tests varies substantially across US hospitals and insurers. Variation is greater between hospitals than within for the same test—with implications for spending, patient out-of-pocket costs & equitable access to guideline-recommended #cancer care. @ASCO @SmilowCancer @OncoAlert @YaleCOPPER

[Yale Cancer Center @YaleCancer]

At #ASCO26, Dr. David Rimm @yalepathology discussed new data suggesting #AI can “read” standard #pathology slides to infer molecular signals that usually require extra lab tests, a potentially faster and more accessible method. Still research, not yet a replacement for today’s validated companion diagnostics. @ASCO @SmilowCancer @OncoAlert

[Yale Cancer Center @YaleCancer]

Drs. Alessandro Santin and Stefania Bellone share promising data on a ph II study (NCT06028932) of sacituzumab govitecan for #ovariancancer: 35% had tumor shrinkage and 40% had stable disease in 20 heavily pretreated patients. #ASCO26 @ASCO @SmilowCancer @OncoAlert

[Yale Cancer Center @YaleCancer]

Stop by Hall A this afternoon at 1:30pm CDT as we have 4 presenters sharing research updates and study results: Drs. @NicholasBlondin; Sylvia Kurz @NeurologyYale; Tamar Kaminski; and @AdrianaKahnMD.
@SmilowCancer @YaleBreast @ASCO

[Yale Cancer Center @YaleCancer]

.@Durga_Sritharan shows how using #AI on ovarian cancer pathology slides can flag tumors likely to resist platinum chemo (about 1/5 patients). In validation, “predicted sensitive” slides were correct 79% of the time, supporting a low-cost tool to personalize treatment earlier. #ASCO26 @ASCO @SmilowCancer @yalepathology @OncoAlert

[Yale Cancer Center @YaleCancer]

.@sundar__raghav chairs an education session on Targeting Metastatic Niches and also will present 'Foundations of Premetastatic Niche Formation' today at 1:15pm CDT #ASCO26.
https://t.co/UNEhrSuokc
@SmilowCancer @YaleGICancers @ASCO

[Yale Cancer Center @YaleCancer]

Gabriela Esnaola @YaleMed shares #ASCO26 a study of metastatic #NSCLC showing that patterns of where cancer spreads predict survival & treatment response better than looking at single organs alone. This “metastasis profile” approach could improve therapy decisions. @ASCO @ishizukalab @OncoAlert @YaleSurgery